CCR4 and CCR5 expression in conjunctival specimens as differential markers of TH1/TH2 in ocular surface disorders

被引:62
作者
Baudouin, C
Liang, H
Bremond-Gignac, D
Hamard, P
Hreiche, R
Creuzot-Garcher, C
Warnet, JM
Brignole-Baudouin, F
机构
[1] Quinze Vingts Natl Ophthalmol Hosp, Dept Ophthalmol, F-75012 Paris, France
[2] Univ Versailles, Hop Ambroise Pare, APHP, Paris Ouest Sch Med, F-78000 Versailles, France
[3] INSERM, U598, Inst Biomed Cordeliers, Paris, France
[4] Univ Paris 07, Robert Debre Hosp, APHP, Dept Ophthalmol, F-75221 Paris 05, France
[5] Univ Paris 05, Fac Biol & Pharmacol Sci, Dept Toxicol, F-75270 Paris 06, France
[6] Burgundi Univ, Univ Hosp Dijon, Dept Ophthalmol, Dijon, France
关键词
CCR4; CCR5; conjunctiva; flow cytometry; glaucoma; HLA-DR; impression cytology; Sjogren syndrome; T(H)1; T(H)2;
D O I
10.1016/j.jaci.2005.05.033
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Accurate inflammatory mechanisms in chronic ocular surface diseases (OSDs) cannot routinely be assessed. New techniques for investigating ocular surface inflammatory pathways are of major importance. Objective: To investigate the expressions of CCR4 and CCR5, known to be related to the T(H)2 and T(H)1 systems, respectively, and HLA-DR in conjunctival impression cytology specimens from patients with chronic OSDs. Methods: In this case-controlled study, impression cytology specimens were taken in a series of patients with vernal keratoconjunctivitis (n = 21), giant papillary conjunctivitis (n = 6), or keratoconjunctivitis sicca (KCS; n = 17), or receiving topical antiglaucoma treatments (n = 31), and from 20 normal subjects. Conjunctival cells were incubated with mAbs to CCR4, CCR5, CD45, and HLA-DR to quantify conjunctival inflammation in a masked manner using flow cytometry. Results: HLA-DR was higher in the glaucoma and KCS groups than in allergic and normal eyes. CCR4 was overexpressed in allergy and glaucoma, whereas CCR5 was higher in the KCS and glaucomatous groups. CD45 was expressed by only few cells in all groups, with almost no significant differences. CCR4 expression was negatively correlated with CCR5 and HLA-DR, whereas CCR5 was positively correlated with HLA-DR. Conclusion: This study confirms the overexpression of chemokine receptors by the conjunctival epithelium in OSDs. CCR4 and CCR5 expression may vary according to the immune pathway involved. Accurate mechanisms in ocular surface inflammatory reactions-that is, those related to the T(H)1 or T(H)2 systems-could be differentiated by CCR4/CCR5 profiles. Our results also suggest that long-term use of topical treatments may stimulate both systems.
引用
收藏
页码:614 / 619
页数:6
相关论文
共 24 条
[1]   C-C chemokine receptor 4 expression defines a major subset of circulating nonintestinal memory T cells of both Th1 and Th2 potential [J].
Andrew, DP ;
Ruffing, N ;
Kim, CH ;
Miao, WY ;
Heath, H ;
Li, Y ;
Murphy, K ;
Campbell, JJ ;
Butcher, EC ;
Wu, LJ .
JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :103-111
[2]  
Baudouin C, 1997, INVEST OPHTH VIS SCI, V38, P1458
[3]   Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis [J].
Baudouin, C ;
Bourcier, T ;
Brignole, F ;
Bertel, F ;
Moldovan, M ;
Goldschild, M ;
Goguel, A .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2000, 238 (11) :900-904
[4]   Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term [J].
Baudouin, C ;
Hamard, P ;
Liang, H ;
Creuzot-Garcher, C ;
Bensoussan, L ;
Brignole, F .
OPHTHALMOLOGY, 2004, 111 (12) :2186-2192
[5]   Allergic and immunologic disorders of the eye. Part I: Immunology of the eye [J].
Bielory, L .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2000, 106 (05) :805-816
[6]   Ocular allergy and dry eye syndrome [J].
Bielory, Leonard .
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 4 (05) :421-424
[7]   Vernal keratoconjunctivitis [J].
Bonini, S ;
Coassin, M ;
Aronni, S ;
Lambiase, A .
EYE, 2004, 18 (04) :345-351
[8]  
Brignole F, 2000, INVEST OPHTH VIS SCI, V41, P1356
[9]  
Calder VL, 1999, CLIN EXP ALLERGY, V29, P1214
[10]  
Debbasch C, 2001, INVEST OPHTH VIS SCI, V42, P2525